A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Janssen Research & Development, LLC
- ID
- NCT06211764
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 250 study participants
- Last Updated